more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.

VBI Vaccines (VBIV) to Report Q2 Earnings: What's in Store

by Zacks Equity Research Published on July 28,2020

VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.

pharmaceuticals

ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 28,2020

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

biotechs

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 24,2020

Alexion (ALXN) will provide financial and corporate updates when it releases second-quarter 2020 results on Jul 30.

biotechs

Earnings Preview: Alexion Pharmaceuticals (ALXN) Q2 Earnings Expected to Decline

by Zacks Equity Research Published on July 23,2020

Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXNPositive Net Change

Alexion Pharmaceuticals (ALXN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on July 15,2020

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXNPositive Net Change

Equillium Gains From Positive Results on Coronavirus Drug

by Zacks Equity Research Published on July 14,2020

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

biotechs

Gilead Presents Additional Data on Coronavirus Drug Remdesivir

by Zacks Equity Research Published on July 13,2020

Gilead (GILD) announces a comparative analysis of remdesivir, wherein the drug was associated with a 62% reduction in risk of mortality compared to standard of care.

biotechs

Gilead Starts Testing Remdesivir Inhaled Version for Coronavirus

by Zacks Equity Research Published on July 09,2020

Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.

biotechs

Gilead's Coronavirus Drug Gets Conditional Approval in Europe

by Zacks Equity Research Published on July 06,2020

Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.

biotechs

Why the Earnings Surprise Streak Could Continue for Alexion (ALXN)

by Zacks Equity Research Published on July 02,2020

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ALXNPositive Net Change

Gilead's Coronavirus Drug Being Stocked by the US Government

by Zacks Equity Research Published on July 02,2020

Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.

biotechs

Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

by Zacks Equity Research Published on July 01,2020

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

biotechs

Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial

by Zacks Equity Research Published on June 30,2020

Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.

biotechs

Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation

by Zacks Equity Research Published on June 26,2020

Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.

biotechs

Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III

by Zacks Equity Research Published on June 25,2020

Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.

biotechs

Zealand Announces Dosing Initiation in Type 2 Diabetes Study

by Zacks Equity Research Published on June 25,2020

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.